Nurix reports Phase 1a/1b data for bexobrutideg: ORR 83% in R/R CLL, 92.9% in earlier-line

Nurix Therapeutics, Inc.

Phase 1a ORR 83.0% (47 evaluable), median PFS 22.1 months; median 4 prior lines.
Phase 1b Cohort 5 (BTKi-treated, BCL2i-naïve): ORR 92.9% at 5.2 months follow-up; 18/19 on treatment.
Phase 1b Cohort 15 (BTKi-naïve, incl. treatment-naïve): ORR 84.2% at 4.9 months; 19/20 on treatment.
Safety: well-tolerated, no dose-limiting toxicities, no treatment-related Grade 5 events; AE discontinuation 5.6%.
Company plans Phase 3 monotherapy program and has Roche collaboration.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.